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INTRODUCTION
Genetic instability, inactivation of tumor suppressor genes, 
activation of oncogenes, as well as expression of growth factors, 
cytokines, and angiogenic factors promote tumor progression 
and invasion. Many angiogenic factors, including fibroblast 
growth factor, vascular endothelial growth factor (VEGF), and 
platelet-derived endothelial cell growth factor have been iden-
tified [1]. One of the most potent and specific angiogenic cyto-
kines is VEGF. It is a 23 to -45 kDa heparin-binding glycopro-
tein that exerts multiple effects on tumors, including stimulat-
ing the formation of new blood and lymphatics vessels and in-
creasing vascular permeability [2]. Binding of VEGF to one of 
several tyrosine kinase receptors triggers their autophosphor-
ylation resulting in the activation of mitogen-activated protein 
kinases. Breast cancer has overtaken cervical cancer to become 
the leading cause of cancer-related mortality in females world-
wide. The etiology of breast cancer is multifactorial. Hormo- 
nal, genetic, and environmental factors appear to interplay in 
the pathogenesis of breast cancer [3], and oxidative stress has 
been suggested to play a role in malignant transformation [4].
A number of studies have unraveled the role of estrogens as 
well as the imbalance in oncogenes and tumor suppressor genes 
in breast cancer, but only a few reports are available on the oxi-
dant-antioxidant profile in patients with breast cancer. Although 
reactive oxygen species (ROS), normal byproducts of aerobic 
metabolism, are essential for various defense mechanisms in 
most cells, they can also cause oxidative damage to DNA, pro-
teins, and lipids resulting in enhanced cancer risk [5].
Malondialdehyde (MDA), the end-product of lipid peroxi-
dation (LPO) arising from the free radical degradation of poly-
unsaturated fatty acids, can cause cross-linking in lipids, pro-
teins, and nucleic acids [6,7]. VEGF is up-regulated by condi-
tions associated with the generation of free radicals and reac-
tive oxygen intermediates [8]. However, the exact pathomech-
anism causing this malignant transformation is still unclear. 
The present study investigated the possible association between 
oxidative stress status and serum VEGF levels in patients with 
breast cancer.
 
Vascular Endothelial Growth Factor Levels in Relation to Oxidative Damage 
and Antioxidant Status in Patients with Breast Cancer
Deepti Pande, Reena Negi, Seema Khanna, Ranjana Khanna
1, Hari D. Khanna
Institute of Medical Sciences,
 1Faculty of Science, Banaras Hindu University, Varanasi, India
ORIGINAL ARTICLE
J Breast Cancer 2011 September; 14(3): 181-184  http://dx.doi.org/10.4048/jbc.2011.14.3.181
Purpose: Oxidative stress and angiogenesis are important ele-
ments in the pathogenesis of inflammatory diseases and cancer. 
Vascular endothelial growth factor (VEGF) is one of the most     
potent angiogenic cytokines and is up-regulated by conditions 
associated with the generation of free radicals and reactive oxy-
gen intermediates. In this study, we investigated the association 
between oxidative stress and serum VEGF status in patients with 
breast cancer. Methods: Forty patients with breast carcinoma, of 
which 21 were stage II and 19 were stage III, along with 40 age- 
and gender-matched healthy controls were enrolled. Oxidative 
stress, total antioxidant status, and VEGF levels in serum were 
evaluated by spectrophotometric procedures. Malondialdehyde 
(MDA) levels were measured and antioxidant status was assessed 
by measuring total antioxidant status (TAS) to assess oxidative 
damage. Results: VEGF and MDA levels were significantly higher in 
patients with breast cancer than those of controls (p<0.005). Total 
antioxidant level decreased significantly in patients compared to 
that in controls. MDA, TAS, and VEGF levels were also analyzed 
based on menopausal status and different clinical disease stages. 
MDA and TAS level significantly different in the postmenopausal 
group than the premenopausal group, whereas VEGF level re- 
ma  ined unchanged. Conclusion: Increased VEGF level and its 
positive correlation with oxidative stress level and decreased   
antioxidant status suggest a link between oxidative stress and 
malignant transformation.
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METHODS
The study included 40 patients with clinically diagnosed 
breast carcinoma, who were transferred to the department of 
general surgery, Banaras Hindu University Hospital, for treat-
ment. Patients who did not undergo chemotherapy or radio-
therapy were included. Clinical breast cancer staging was per-
formed according to the TNM-UICC classification [9]. The 
controls consisted of 40 age and gender-matched healthy vol-
unteers with a socio-economic status similar to that of the pa-
tients. They had no acute or chronic diseases such as diabetes, 
parasites, or any immune dysfunction. Additionally, the con-
trols had normal leukocyte levels and other blood cell counts 
and were not under any pharmacological therapy. Venous blood 
was collected from patients and healthy volunteers into sterile 
tubes and the serum was used for various biochemical and 
hematological analyses.
The Institutional Review Board of the Institute of Medical 
Sciences, Banaras Hindu University approved the study (no. 
Dean/2010-11/65). Informed consent was obtained from each 
patient and the healthy volunteers to collect blood samples.
Reagents
All chemicals and reagents were of analytical grade from 
Sigma-Aldrich Co. (St. Louis, USA).
Lipid oxidative damage assay
Oxidative damage in the serum of patients and healthy con-
trols was assessed by measuring LPO products in serum using 
the thiobarbituric acid (TBA) method [10]. MDA, which is a 
stable end- product of fatty acid peroxidation, reacts with TBA 
under acidic conditions to form a complex that has a maximum 
absorbance at 532 nm.
Total antioxidant status (TAS) assay
Serum TAS was determined using an assay kit (Randox Lab-
oratories Ltd., Crumlin, UK) [11]. The assay was based on the 
principle that ABTS (2, 2´-azino-di-[3-ethylbenzthiazoline-6-
sulfonate]) produces the radical cation ABTS+ upon incuba-
tion with a peroxidase and H2O2. This reaction produces a rel-
atively stable blue green color that is measured at 600 nm. An-
tioxidants in the serum suppress color production proportion-
al to their concentration.
VEGF levels
VEGF levels were measured with a commercially available 
enzyme-linked immunosorbent assay kit (Thermo Scientific, 
Rockford, USA), according to the manufacturers protocol. The 
microplate used for the assay was coated with anti-human VEGF 
antibody, which captures VEGF in the standard and samples 
added to the plate. After removing of unbound proteins, a bio-
tinylated detecting antibody is added and allowed to bind to 
the VEGF. Excess antibody is removed and streptavidin-horse-
radish peroxidase is added, which reacts with 3,3´,5,5´-tetra-
methylbenzidine (TMB) to produce a colorimetric signal. The 
lower limit of detection for VEGF was <8.0 pg/mL.
Statistical analysis
The statistical analyses were conducted with the commercial 
SPSS version 16.0 package for Windows (SPSS Inc., Chicago, 
USA). All data are expressed as the mean±standard error of 
the mean (SEM). Data were analyzed with the independent 
Student’s t-test. All statistical analyses were two-tailed and a p-
value <0.05 was considered statistically significant.
Correlation between oxidative stress levels and VEGF was 
evaluated with Pearson’s correlation coefficient. A p-value <0.05 
was considered as statistically significant.
 
RESULTS
MDA, TAS, and VEGF were estimated among the patients 
with breast cancer in relation to their clinical stages and meno-
pausal status, respectively. The patients were clinically classified 
as stage II (21 patients) and III B (19 patients), according to the 
UICC TNM system (Table 1). Of the 40 patients with breast 
cancer, 23 were premenopausal and 17 were postmenopausal. 
Table 2 shows the changes in VEGF levels as a result of oxida-
tive damage and associated total antioxidant levels in patients 
with breast cancer with respect to their corresponding controls. 
The results revealed that the VEGF and MDA levels were sig-
nificantly higher in patients with breast cancer than those in the 
controls (p<0.05). The total antioxidant level decreased signif-
icantly in patients compared to that in controls. Table 3 shows 
the correlations between levels of oxidative stress, TAS and VEGF 
in patients with breast cancer. The VEGF levels were significantly 
and positively correlated with oxidative stress, whereas total an-
tioxidant level was significantly and negatively correlated with 
Table 1. Patients’ characteristics (n=40)
Variable No. of patients (%) 
Age (mean±SD, yr) 46.5±11.23
Menopausal status
   Premenopausal     23 (57.5 )
   Postmenopausal    17 (42.5)
Stage
   II A      7 (17.5)
   II B 14 (35)
   III A    11 (27.5)
   III B   8 (20)AngiogenesisandOxidativeStress 183
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VEGF. At the same time, MDA and TAS were significantly and 
negatively correlated. MDA, TAS, and VEGF levels measured 
in patients with breast cancer in relation to their menopausal 
status are depicted in Table 4. The levels of VEGF and TAS were 
not altered significantly in relation to menopausal status but 
there were significant changes in the MDA levels in the patients. 
MDA, TAS, and VEGF levels were studied in relation to their 
clinical stage (stages II and III) (Table 5). VEGF and MDA levels 
tended to increase at higher clinical stages of cancer, whereas 
the total antioxidant levels decreased with increasing stage.
DISCUSSION
At the onset, the process of angiogenesis requires a change 
in the local equilibrium between proangiogenic and antian-
giogenic factors [12]. Oxidative stress, after causing nonlethal 
injury to cells, may initiate a signal transduction cascade lead-
ing to tissue repair and angiogenesis [13]. Endothelial and in-
flammatory cells release high concentrations of angiogenesis 
activators, such as VEGF, angiopoietin-1, fibroblast growth 
factor, and transforming growth factor. Excess generation of 
oxygen derived radicals can cause oxidative damage [14]. Data 
also indicate that ROS are involved in initiating and promoting 
cancer. Our results showed a correlation between serum levels 
of oxidative stress and VEGF in patients with breast cancer prior 
to treatment initiation. MDA levels were significantly higher in 
the blood of patients with breast cancer compared to those in 
the controls. Simultaneously, TAS concentrations were reduced 
significantly in patients with breast cancer compared to those 
in the controls. Our findings agree with most previous studies 
suggesting that ROS may accumulate due to decreased antiox-
idant levels in the blood, which may cause significantly higher 
LPO at the cellular and molecular levels.
MDA increased significantly in patients with breast cancer, 
Table 2.  Levels of VEGF, MDA, and TAS in breast carcinoma patients and control cases
  Control (n=40)   Cases (n=40) p-value T-value
VEGF (pg/mL) 464.223±31.352 622.3119±22.211   0.0001* 4.114
MDA (mM/L) 3.0258±0.189 3.94467±0.267 0.006* 2.802
TAS (mM/L)     1.815±0.0692       1.419±0.1039 0.002* 3.176
Values are presented as mean±SEM.
VEGF=vascular endothelial growth factor; MDA= malondialdehyde; TAS=total antioxidant status.    
*Statistical analysis was done by independent Student’s t-test. All statistical analyses were two-tailed and a value of p<0.05 was considered statistically significant.
Table 3. Correlation between VEGF, MDA, and TAS in breast carcinoma 
patients
VEGF (n=40) MDA (n=40) TAS (n=40)
Pearson correlation
   VEGF  -  0.376*     0.534
†
   MDA      0.376* -     0.312*
   TAS      0.534
†  0.312*  -
Significance (two tailed)
   VEGF  - 0.017 <0.001
   MDA    0.017 -    0.044
   TAS <0.001 0.044  -
VEGF=vascular endothelial growth factor; MDA=malondialdehyde; TAS=total 
antioxidant status.
*Correlation is significant at the 0.05 level (2-tailed); 
†Correlation is significant 
at the 0.01 level (2-tailed).
Table 4. Levels of VEGF, MDA, and TAS in breast carcinoma patients in relation to their menopausal status 
   Premenopausal (n=22)    Postmenopausal (n=18) p-value T-value
VEGF (pg/mL)     600.1214±30.274063 649.43351±32.4456 0.275 -1.108
MDA (mM/L)         3.4146±0.3040367           4.5925±0.4246482    0.026* -2.309
TAS (mM/L) 1.58376±0.1697       1.21798±0.085366 0.080   1.800 
Values are presented as mean±SEM.
VEGF=vascular endothelial growth factor; MDA=malondialdehyde; TAS=total antioxidant status.
*Statistical analysis was done by independent Student’s t-test. All statistical analyses were two-tailed and a value of p<0.05 was considered statistically significant.
Table 5. Levels of VEGF, MDA, and VEGF in breast carcinoma patients in relation to the clinical stage
  II A (n=7)   II B (n=14)   III A (n=11)  III B (n=8)
VEGF (pg/mL) 511.021±37.676 550.532±31.266 703.547±35.604 733.605±33.309
MDA (mM/L)   2.800±0.466   3.307±0.536   4.576±0.261   5.192±0.439
TAS (mM/L)   1.828±0.201   1.633±0.227   1.186±0.093   1.005±0.131
Values are presented as mean±SEM.
VEGF=vascular endothelial growth factor; MDA=malondialdehyde; TAS=total antioxidant status. 184  DeeptiPande,etal.
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which represents the oxidation of polyunsaturated fatty acids 
in membranes induced by free radicals. Lipid peroxides are 
well-characterized mutagens and are cytotoxic to the endothe-
lial cells.
Therefore, an increase in MDA, a LPO product, could indi-
cate involvement of endothelial cell dysfunction in tumor patho-
physiology. Accompanying the accumulation of oxidative dam-
age products, a significant reduction in total antioxidant cap- 
acity measured in the sera of patients with breast cancer was 
observed. Changes in TAS levels also reflected disease progres-
sion [15]. VEGF is widely recognized as a significant stimula-
tor of tumor angiogenesis [16], and its cellular expression is 
regulated by a plethora of external factors. Cytokines, growth 
factors, and gonadotropins, which do not stimulate angiogen-
esis directly, can modulate angiogenesis by modulating VEGF 
expression in specific cell types and, thus, exert an indirect an-
giogenic or anti-angiogenic effect. The exact pathomechanism 
of this transformation is unknown.
Previous studies have shown that oxidative stress stimulates 
angiogenesis in cultured endothelial cells [17], which may acti-
vate angiogenesis for cancer. In this study, VEGF and MDA 
levels increased simultaneously and were positively correlated, 
which might indicate a cause or effect of the disease. The angio-
genic response in vascular tissue is triggered by reactive oxygen 
species signaling. In cancer cells, a chronic imbalance in redox 
status, results in excessive ROS production, including H2O2. 
Additionally, low concentrations of H2O2, play various physi-
ological roles, such as regulating gene expression and endothe-
lial cell proliferation. Furthermore, H2O2 up regulates nuclear 
factor-κB, which, in turn, regulates VEGF mRNA in breast cancer 
cells, supporting its role in angiogenesis and breast cancer me-
tastasis [18,19]. Therefore, release of H2O2 might be triggers for 
the angiogenic process in cancer cells. Potent suppressors of ROS 
formation in humans may be a target for new cancer therapy.
A significant increase in MDA level was found in the post-
menopausal group associated with decreases in TAS, whereas 
VEGF levels were not altered significantly. The decreased TAS 
levels in postmenopausal women agree with a previous study [20]. 
Taken together, our results suggest a functional interplay 
among oxidative stress, antioxidants, and VEGF in patients 
with breast cancer. High levels of VEGF in patients with breast 
cancer were paralleled by elevated oxidative damage and de-
creased antioxidant levels. 
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